Vegfr3-CreER (T2) mouse, a new genetic tool for targeting the lymphatic system
Standard
Vegfr3-CreER (T2) mouse, a new genetic tool for targeting the lymphatic system. / Martinez-Corral, Ines; Stanczuk, Lukas; Frye, Maike; Ulvmar, Maria Helena; Diéguez-Hurtado, Rodrigo; Olmeda, David; Makinen, Taija; Ortega, Sagrario.
in: ANGIOGENESIS, Jahrgang 19, Nr. 3, 07.2016, S. 433-45.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Vegfr3-CreER (T2) mouse, a new genetic tool for targeting the lymphatic system
AU - Martinez-Corral, Ines
AU - Stanczuk, Lukas
AU - Frye, Maike
AU - Ulvmar, Maria Helena
AU - Diéguez-Hurtado, Rodrigo
AU - Olmeda, David
AU - Makinen, Taija
AU - Ortega, Sagrario
PY - 2016/7
Y1 - 2016/7
N2 - The lymphatic system is essential in many physiological and pathological processes. Still, much remains to be known about the molecular mechanisms that control its development and function and how to modulate them therapeutically. The study of these mechanisms will benefit from better controlled genetic mouse models targeting specifically lymphatic endothelial cells. Among the genes expressed predominantly in lymphatic endothelium, Vegfr3 was the first one identified and is still considered to be one of the best lymphatic markers and a key regulator of the lymphatic system. Here, we report the generation of a Vegfr3-CreER (T2) knockin mouse by gene targeting in embryonic stem cells. This mouse expresses the tamoxifen-inducible CreER(T2) recombinase under the endogenous transcriptional control of the Vegfr3 gene without altering its physiological expression or regulation. The Vegfr3-CreER (T2) allele drives efficient recombination of floxed sequences upon tamoxifen administration specifically in Vegfr3-expressing cells, both in vitro, in primary lymphatic endothelial cells, and in vivo, at different stages of mouse embryonic development and postnatal life. Thus, our Vegfr3-CreER (T2) mouse constitutes a new powerful genetic tool for lineage tracing analysis and for conditional gene manipulation in the lymphatic endothelium that will contribute to improve our current understanding of this system.
AB - The lymphatic system is essential in many physiological and pathological processes. Still, much remains to be known about the molecular mechanisms that control its development and function and how to modulate them therapeutically. The study of these mechanisms will benefit from better controlled genetic mouse models targeting specifically lymphatic endothelial cells. Among the genes expressed predominantly in lymphatic endothelium, Vegfr3 was the first one identified and is still considered to be one of the best lymphatic markers and a key regulator of the lymphatic system. Here, we report the generation of a Vegfr3-CreER (T2) knockin mouse by gene targeting in embryonic stem cells. This mouse expresses the tamoxifen-inducible CreER(T2) recombinase under the endogenous transcriptional control of the Vegfr3 gene without altering its physiological expression or regulation. The Vegfr3-CreER (T2) allele drives efficient recombination of floxed sequences upon tamoxifen administration specifically in Vegfr3-expressing cells, both in vitro, in primary lymphatic endothelial cells, and in vivo, at different stages of mouse embryonic development and postnatal life. Thus, our Vegfr3-CreER (T2) mouse constitutes a new powerful genetic tool for lineage tracing analysis and for conditional gene manipulation in the lymphatic endothelium that will contribute to improve our current understanding of this system.
KW - Animals
KW - Female
KW - Gene Expression Regulation, Developmental
KW - Gene Knock-In Techniques
KW - Integrases
KW - Lymphatic System
KW - Mice
KW - Mice, 129 Strain
KW - Mice, Inbred C57BL
KW - Mice, Transgenic
KW - Pregnancy
KW - Tamoxifen
KW - Vascular Endothelial Growth Factor Receptor-3
KW - Journal Article
U2 - 10.1007/s10456-016-9505-x
DO - 10.1007/s10456-016-9505-x
M3 - SCORING: Journal article
C2 - 26993803
VL - 19
SP - 433
EP - 445
JO - ANGIOGENESIS
JF - ANGIOGENESIS
SN - 0969-6970
IS - 3
ER -